CA2774732A1 - Dosage regimen for administering an epcamxcd3 bispecific antibody - Google Patents

Dosage regimen for administering an epcamxcd3 bispecific antibody Download PDF

Info

Publication number
CA2774732A1
CA2774732A1 CA2774732A CA2774732A CA2774732A1 CA 2774732 A1 CA2774732 A1 CA 2774732A1 CA 2774732 A CA2774732 A CA 2774732A CA 2774732 A CA2774732 A CA 2774732A CA 2774732 A1 CA2774732 A1 CA 2774732A1
Authority
CA
Canada
Prior art keywords
bispecific antibody
dose
period
epcamxcd3 bispecific
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2774732A
Other languages
English (en)
French (fr)
Inventor
Gerhard Zugmeier
Peter Kufer
Dominik Ruettinger
Sabine Kaubitzsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Micromet GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet GmbH filed Critical Micromet GmbH
Publication of CA2774732A1 publication Critical patent/CA2774732A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2774732A 2009-09-18 2010-09-20 Dosage regimen for administering an epcamxcd3 bispecific antibody Abandoned CA2774732A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US24365109P 2009-09-18 2009-09-18
EP09170715.8 2009-09-18
EP09170715 2009-09-18
US61/243,651 2009-09-18
US34414710P 2010-06-01 2010-06-01
EP10164596.8 2010-06-01
US61/344,147 2010-06-01
EP10164596 2010-06-01
PCT/EP2010/063795 WO2011033105A1 (en) 2009-09-18 2010-09-20 Dosage regimen for administering an epcamxcd3 bispecific antibody

Publications (1)

Publication Number Publication Date
CA2774732A1 true CA2774732A1 (en) 2011-03-24

Family

ID=43127167

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2774732A Abandoned CA2774732A1 (en) 2009-09-18 2010-09-20 Dosage regimen for administering an epcamxcd3 bispecific antibody

Country Status (15)

Country Link
US (1) US20120244161A1 (https=)
EP (1) EP2477653A1 (https=)
JP (1) JP2013505223A (https=)
KR (1) KR20120083359A (https=)
CN (1) CN102711825A (https=)
AU (1) AU2010297258A1 (https=)
BR (1) BR112012008345A2 (https=)
CA (1) CA2774732A1 (https=)
IL (1) IL218637A0 (https=)
IN (1) IN2012DN03172A (https=)
MX (1) MX2012003175A (https=)
NZ (1) NZ598601A (https=)
RU (1) RU2012115480A (https=)
SG (2) SG10201405434VA (https=)
WO (1) WO2011033105A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
UY34504A (es) 2011-12-09 2013-06-28 Amgen Res Munich Gmbh Prevención de los efectos adversos causados por los anticuerpos biespecíficos EpCAMxCD3
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014127215A1 (en) 2013-02-15 2014-08-21 Biogen Idec Ma Inc. Optimized factor viii gene
EP2961773B1 (en) * 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
CN106456748A (zh) * 2014-01-08 2017-02-22 小利兰·斯坦福大学托管委员会 小细胞肺癌的靶向疗法
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
FI3377103T4 (fi) * 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
CA3012695A1 (en) 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Optimized factor viii genes
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
WO2017167350A1 (en) * 2016-03-30 2017-10-05 Horst Lindhofer Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
EP3409322A1 (en) * 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
CN111356700A (zh) 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
EP4592313A3 (en) 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
KR20220097891A (ko) 2019-09-30 2022-07-08 바이오버라티브 테라퓨틱스 인크. 렌티바이러스 벡터 제형
MX2023000156A (es) 2020-06-24 2023-02-16 Bioverativ Therapeutics Inc Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina.
MX2024006079A (es) * 2021-11-19 2024-07-29 Wuhan Yzy Biopharma Co Ltd Anticuerpo biespecifico y uso del mismo.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
PL1874821T3 (pl) * 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka

Also Published As

Publication number Publication date
SG179027A1 (en) 2012-04-27
AU2010297258A1 (en) 2012-03-29
MX2012003175A (es) 2012-04-11
WO2011033105A1 (en) 2011-03-24
CN102711825A (zh) 2012-10-03
IL218637A0 (en) 2012-05-31
EP2477653A1 (en) 2012-07-25
RU2012115480A (ru) 2013-10-27
SG10201405434VA (en) 2014-10-30
JP2013505223A (ja) 2013-02-14
KR20120083359A (ko) 2012-07-25
IN2012DN03172A (https=) 2015-09-25
US20120244161A1 (en) 2012-09-27
BR112012008345A2 (pt) 2016-08-09
NZ598601A (en) 2014-05-30

Similar Documents

Publication Publication Date Title
US20120244161A1 (en) DOSAGE REGIMEN FOR ADMINISTERING AN EpCAMxCD3 BISPECIFIC ANTIBODY
US20230235060A1 (en) Neutralization of inhibitory pathways in lymphocytes
US11498972B2 (en) Anti-OX40 antibody and use thereof
JP2025139586A (ja) ヒトのがんを治療するための特異的抗ｃｄ３８抗体
EP3137502B1 (en) Humanized antibodies against ceacam1
CN107207593A (zh) 抗pd‑1抗体及其使用方法
US20250367313A1 (en) Antibodies specific to muc18
WO2021228178A1 (en) Compositions and methods for treating cancer
ES2825625T3 (es) Anticuerpos anti-CD38 específicos para tratar cánceres humanos
AU2012350429A1 (en) Prevention of adverse effects caused by EpCAMxCD3 bispecific antibodies
JP2024519907A (ja) 尿路上皮癌の治療における、免疫チェックポイント阻害剤と併用での抗体薬物複合体の使用
EP4346887A1 (en) C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
CN109793892B (zh) 一种抗pd-1抗体在制备治疗食管癌的药物中的用途
KR20250075750A (ko) 항-ctla4 항체를 사용한 암의 치료 방법
CN120225561A (zh) 用于癌症新辅助治疗的包含抗cd39抗体的组合物和方法
HK40110316A (en) Neutralization of inhibitory pathways in lymphocytes
CN114316046A (zh) 一种稳定的抗体组合物
HK40078924A (en) Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
HK1223116B (en) Specific anti-cd38 antibodies for treating human cancers

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130911

FZDE Discontinued

Effective date: 20160219